Related Experiment Video
Updated: Apr 29, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Prostate cancer epigenetic biomarkers: next-generation technologies.
11] Epigenetics Laboratory, Cancer Research Division Cancer Research Program and The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia [2] St Vincent's Clinical School, St Vincent's Hospital and University of New South Wales, Darlinghurst, NSW, Australia.
Cancer arises from genetic mutations and epigenetic changes affecting gene regulation. Understanding these epigenetic aberrations in prostate cancer offers new biomarker potential for detection and treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Pathology
Background:
- Cancer development involves genetic alterations and epigenetic landscape changes, leading to aberrant gene regulation.
- Epigenetic aberrations are crucial in cancer initiation and progression, impacting all cancer types, including prostate cancer.
- Understanding epigenetics is vital for advancing molecular pathology in cancer detection and treatment.
Purpose of the Study:
- To review common epigenetic aberrations in prostate cancer with biomarker potential.
- To describe current epigenomic technologies for identifying epigenetic changes in prostate cancer.
- To discuss future translational applications in molecular pathology for prostate cancer detection and prognosis.
Main Methods:
- Literature review of epigenetic aberrations in prostate cancer.
- Analysis of current epigenomic technologies.
- Discussion of translational applications in molecular pathology.
Main Results:
- Common epigenetic aberrations in prostate cancer with biomarker potential identified.
- Innovative and current epigenomic technologies for prostate cancer analysis are described.
- Future translational applications for cancer detection and prognosis are outlined.
Conclusions:
- Epigenetic aberrations are key drivers in prostate cancer.
- Epigenomic technologies offer powerful tools for prostate cancer research.
- Targeting epigenetic changes holds significant promise for prostate cancer detection and treatment.
